DR Congo Mpox: Overview and Epidemiological Profile
Mpox is a viral disease that causes painful rashes and can be severe in children and people with weak immunity. A new strain spread widely in Central Africa from 2023. This report covers clade i mpox and clade II mpox.
Burden: Prevalence, Incidence and Mortality
The report sets out the prevalence, incidence and, where relevant, deaths from mpox in DR Congo, and the overall burden, using Reported Cases, Case Fatality Rate, Hospital Admissions, Outbreak Frequency and Laboratory Confirmation Rate.
Demographic Distribution: Age, Gender and Vulnerable Population Groups
The burden is broken down by age (children under 5, children 5–14 years, adults 15–64 years and adults 65 years and over), gender and income, with a focus on children under five, older adults, people with weak immunity, health workers, displaced people and people without safe water.
Geographical Distribution: State, District, Urban and Rural Segmentation
Findings are compared across states, provinces and districts where data allows, and between urban, rural and informal settlement areas, to show where needs are greatest and where gaps between places are widest.
Risk Factors and Social Determinants of Health
Main risk factors include unsafe water and food, contact with animals, crowding and displacement, weak infection control, climate and seasonal change and low vaccination. Income, education, housing, water and sanitation, and gender and social norms are reviewed as social drivers of health.
Awareness and Screening Coverage
The report reviews how aware people are of mpox and how far screening reaches them, through clinical surveillance, laboratory confirmation, rapid diagnostic tests and outbreak investigation, by group and by area.
Diagnosis Rates and Undiagnosed Burden
It compares the number of people diagnosed with the estimated number affected, to show the undiagnosed burden and how many people are lost between screening and treatment.
Treatment, Prevention and Coverage
Treatment and prevention covered include vaccination of high-risk groups, testing and isolation, contact tracing and supportive care, with how many people receive treatment and how many stay on it.
Health Outcomes and Complications
Long-term effects covered include deaths, long-term complications, outbreak spread and disruption of health services, along with other conditions that often occur alongside mpox.
Healthcare Infrastructure and Accessibility
The report looks at hospitals and isolation units, public health laboratories, rapid response teams and surveillance systems, the health workforce, and the physical, financial and distance barriers to care, including how people use public and private services.
Economic and Socioeconomic Burden
Mpox in DR Congo: health cover, spending and research
DR Congo scores 41 out of 100 on the WHO universal health coverage index (2023).[1] People pay 38.0% of all health spending out of their own pockets (2023).[2] Money from abroad pays for 37.0% of health spending (2023).[3] ClinicalTrials.gov lists 10 studies on Mpox that are recruiting, active or about to start in DR Congo.[4] Deaths under age 5: 89.7 per 1,000 live births in 2024, the latest World Bank figure for DR Congo.[5]
It describes the costs of mpox to health systems and households, including out-of-pocket spending and lost productivity, and how government, donors and NGOs fund the response.
Government Initiatives and Public Health Interventions
Worldwide guidance and funding for mpox include WHO International Health Regulations (2005), WHO Health Emergencies Programme, Global Outbreak Alert and Response Network (GOARN) and Africa CDC. The report reviews national programmes, donor and NGO funding, and what is known about their impact.
Historical Trends and Comparative Analysis
Year-wise trends and changes across survey rounds are shown and compared with peer countries, with the data collection year and reporting period stated for each figure.
Healthcare Gaps and Unmet Needs
The report names gaps in screening, diagnosis, treatment and access, the high-risk and underserved communities most affected, and where reliable data is missing.
Future Burden and Public Health Outlook
It looks ahead at the likely future burden of mpox, the healthcare it will need and the areas most vulnerable.
Key Findings and Strategic Recommendations
The report closes with key findings, the population groups to prioritise and recommendations on where to target resources. Figures come from WHO Disease Outbreak News, WHO Global Health Observatory, National Disease Surveillance Systems and Africa CDC Epidemic Intelligence Reports. Reported cases, survey estimates and modelled estimates are kept apart, and missing figures are named as data gaps.
The mpox burden in this report is segmented by type, age group, gender, population group, area, socioeconomic status and care setting. Here's a breakdown of the segmentation
By Type
- Clade I Mpox
- Clade II Mpox
By Age Group
- Children Under 5
- Children 5–14 Years
- Adults 15–64 Years
- Adults 65 Years and Over
By Population Group
- Children Under Five
- Older Adults
- People With Weak Immunity
- Health Workers
- Displaced People
- People Without Safe Water
By Area
- Urban
- Rural
- Informal Settlements and Camps
By Socioeconomic Status
- Poorest Households
- Lower-Middle
- Middle
- Upper-Middle
- Richest Households
By Care Setting
- Public Health Facilities
- Private Facilities and Pharmacies
- NGO and Faith-Based Facilities
- Community-Based Care